TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30392735

Group type: EXPERIMENTAL
Intervention: Single-dose oral ondansetron
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 30392813

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation and chemotherapy)
Number of subjects: 338
Study: 30393106

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300 mg/120 mg) orally once daily for 8 weeks (for patients without cirrhosis) or 12 weeks (for patients with compensated cirrhosis)
Number of subjects: 84
Study: 30393582

Group type: EXPERIMENTAL
Intervention: Curative, normofractionated radiotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 30393621

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab (CheckMate-227; NCT02477826)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab (IMPower 150; NCT02366143)
Number of subjects: 0
Study: 30393825

Group type: EXPERIMENTAL
Intervention: Pazopanib with low fat meal (LFM)
Number of subjects: 16
Study: 30394330

Group type: EXPERIMENTAL
Intervention: KLG0 case knees with contralateral radiographic JSN
Number of subjects: 828

Group type: COMPARATOR
Intervention: KLG0 reference knees
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: KLG0 knees with contralateral KLG2 without JSN
Number of subjects: 828
Study: 30394678

Group type: EXPERIMENTAL
Intervention: Long-term combined antiretroviral therapy (ART)
Number of subjects: 395
Study: 30395220

Group type: EXPERIMENTAL
Intervention: Inadequate perioperative prophylaxis in patients with established antibiotic treatment
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Incisional surgical site infections
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Hemorrhage
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Procedure time increases of 1-hour intervals
Number of subjects: 438
Study: 30396014

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (H SC) 600 mg via handheld syringe
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (H SC) 600 mg via single-use injection device
Number of subjects: 240
Study: 30396833

Group type: EXPERIMENTAL
Intervention: Phelan-McDermid syndrome patients
Number of subjects: 11
Study: 30396865

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg per day) added to simvastatin (40 mg per day)
Number of subjects: 18144
Study: 30396906

Group type: EXPERIMENTAL
Intervention: Bioceptive suction cervical retractor (SCR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard single-tooth tenaculum
Number of subjects: 25
Study: 30397066

Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children with TB/HIV coinfection.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children without TB.
Number of subjects: 105
Study: 30397067

Group type: EXPERIMENTAL
Intervention: WCK 5222 (Cefepime-Zidebactam Combination)
Number of subjects: 48
Study: 30397491

Group type: EXPERIMENTAL
Intervention: Diabetes prevention program (D-CLIP)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 550
Study: 30397669

Group type: COMPARATOR
Intervention: sCAMs, MMP-9, TIMP-1, NE levels measured in serum
Number of subjects: 91

Group type: COMPARATOR
Intervention: sCAMs and their sheddases
Number of subjects: 91
Study: 30398220

Group type: EXPERIMENTAL
Intervention: Coronary angiography (CAG)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurement
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Asymptomatic post-procedural elevated hs-cTnI levels
Number of subjects: 220
Study: 30398222

Group type: EXPERIMENTAL
Intervention: Caregiver component added to a life skills programme for adolescent girls (13 caregiver sessions)
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Life skills sessions for adolescent girls (32 sessions)
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Caregiver component added to a life skills programme for adolescent girls
Number of subjects: 1633
Study: 30398223

Group type: EXPERIMENTAL
Intervention: Life skills and safe spaces programme (30 life skills sessions and 8 caregiver sessions)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Life skills and safe spaces programme
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 919
Study: 30398516

Group type: EXPERIMENTAL
Intervention: Higher baseline sex hormone-binding globulin (SHBG) level among men
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: Sex steroids
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: Men with higher SHBG level
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Women
Number of subjects: 2169
Study: 30399021

Group type: EXPERIMENTAL
Intervention: Lidocaine administration (1.5 mg·kg bolus followed by 2 mg·kg·hour continuous infusion, then 1 mg·kg·hour after skin closure)
Number of subjects: 42
Study: 30400729

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) and Asunaprevir (ASV)
Number of subjects: 21
Study: 30400780

Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with carboplatin
Number of subjects: 41
Study: 30400824

Group type: EXPERIMENTAL
Intervention: D-IBS patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: CD patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: D-IBS(+) patients
Number of subjects: 39
Study: 30400834

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Repeated influenza vaccination
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Influenza virus infections
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Vaccine acceptance predictors
Number of subjects: 2000
Study: 30400860

Group type: EXPERIMENTAL
Intervention: Audio-video recording during laparoscopic surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Video only recording
Number of subjects: 41
Study: 30400864

Group type: EXPERIMENTAL
Intervention: Oral alendronate sodium 70 mg plus vitamin D3 5600 IU once weekly for 26 weeks
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 198
Study: 30400986

Group type: EXPERIMENTAL
Intervention: FoundationACT assay
Number of subjects: 81
Study: 30401520

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 78
Study: 30401620

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Questionnaire responses from pregnant women
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Questionnaire responses from HCPs
Number of subjects: 314
Study: 30401669

Group type: EXPERIMENTAL
Intervention: iQOS with HeatSticks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional combustible cigarettes
Number of subjects: 0
Study: 30402265

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 11 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group instructed to not change their physical exercise habits
Number of subjects: 61
Study: 30402565

Group type: EXPERIMENTAL
Intervention: Immediate compression (weekly two-component compression bandages during chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed compression (compression after chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed compression
Number of subjects: 0
Study: 30402593

Group type: EXPERIMENTAL
Intervention: Calcium supplementation integrated into ANC services
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adherence partners providing reminders and support
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Challenges in adherence to calcium supplementation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General acceptability of calcium supplementation
Number of subjects: 32
Study: 30402594

Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 13

Group type: COMPARATOR
Intervention: Skipping breakfast
Number of subjects: 13
Study: 30402678

Group type: EXPERIMENTAL
Intervention: Temsirolimus (20 mg or 25 mg IV weekly) + Bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Temsirolimus + Bevacizumab
Number of subjects: 21
Study: 30403300

Group type: EXPERIMENTAL
Intervention: Cidofovir and intravenous immunoglobulin
Number of subjects: 5
Study: 30404035

Group type: EXPERIMENTAL
Intervention: Non-Hispanic blacks
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 718
Study: 30404572

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30405397

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study: 30405414

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) over Dorsolateral Prefrontal Cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30405426

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 0
Study: 30405526

Group type: EXPERIMENTAL
Intervention: High-intensity Robot-assisted Hand Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30405743

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30406070

Group type: EXPERIMENTAL
Intervention: Nurse-led diabetes self-management education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30406341

Group type: EXPERIMENTAL
Intervention: 401 ± 5 nm blue LED for 30 minutes
Number of subjects: 10
Study: 30406948

Group type: EXPERIMENTAL
Intervention: New imputation method for recurrent event data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative binomial model analysis
Number of subjects: 0
Study: 30407304

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients with CHF
Number of subjects: 3506

Group type: COMPARATOR
Intervention: Atrial fibrillation patients without CHF
Number of subjects: 3506
Study: 30407512

Group type: EXPERIMENTAL
Intervention: Short-term pasteurization of breast milk (62°C for 5 seconds)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Historical controls (not specified intervention)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Short-term pasteurization
Number of subjects: 87

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 87
Study: 30407514

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30407618

Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-24.9)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Overweight BMI (25-29.9)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Obese BMI (30 or higher)
Number of subjects: 185
Study: 30408135

Group type: EXPERIMENTAL
Intervention: wAIHA patients with venous thromboembolic events (VTE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: wAIHA patients without VTE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total bilirubin ≥ 40 μmol/L
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Leucocyte count above 7x10(9)/L
Number of subjects: 48
Study: 30408606

Group type: EXPERIMENTAL
Intervention: Group-based telephone intervention
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Individual telephone counseling
Number of subjects: 528

Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 528
Study: 30408700

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 79
Study: 30408788

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 30409150

Group type: EXPERIMENTAL
Intervention: Greyscale ultrasound (GS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multiparametric ultrasound (mpUS)
Number of subjects: 50
Study: 30409537

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: MD diagnosis
Number of subjects: 459
Study: 30410313

Group type: EXPERIMENTAL
Intervention: Filgrastim (Nivestim™) administered at home
Number of subjects: 171
Study: 30410448

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg daily initially, up titrated to 0.4 mg daily in 2 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30410720

Group type: EXPERIMENTAL
Intervention: Temsirolimus (20 mg/m)
Number of subjects: 15
Study: 30410772

Group type: EXPERIMENTAL
Intervention: Multi-sensor platform assessment at preoperative baseline, 3, 6, and 12 months postoperatively
Number of subjects: 100
Study: 30410781

Group type: EXPERIMENTAL
Intervention: domperidone (14-day treatment)
Number of subjects: 90
Study: 30410783

Group type: EXPERIMENTAL
Intervention: MT4C-In Care web-based intervention
Number of subjects: 37
Study: 30411081

Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Osteopontin (OPN)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Monocyte Chemoattractant Protein 1 (MCP1)
Number of subjects: 97
Study: 30411151

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stents (DES)
Number of subjects: 905
Study: 30411246

Group type: EXPERIMENTAL
Intervention: Discontinuation of hydroxyethyl starch (HES) solutions
Number of subjects: 2170
Study: 30411313

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided popliteal sciatic and saphenous ropivacaine block anaesthesia
Number of subjects: 21
Study: 30411727

Group type: EXPERIMENTAL
Intervention: Young subjects (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Old subjects (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Female healthy volunteers in both groups
Number of subjects: 20
Study: 30412238

Group type: EXPERIMENTAL
Intervention: Golimumab (subcutaneous); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DT-EIA (drug-tolerant EIA); specific details not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original-EIA; specific details not mentioned.
Number of subjects: 0
Study: 30412493

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (1.0 mg/kg)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (2.0 mg/kg)
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (all doses)
Number of subjects: 2452
Study: 30412681

Group type: EXPERIMENTAL
Intervention: Stable-isotope dilution ultraperformance chromatography multistage MS-based method for quantifying cortisol and 16 metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable-isotope dilution ultraperformance chromatography multistage MS-based method
Number of subjects: 0
Study: 30412926

Group type: EXPERIMENTAL
Intervention: Home-based HIV services including rapid HIV testing and counselling, support for linkage to and retention in clinic-based HIV care.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Home-based HIV services
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Home-based services
Number of subjects: 146
Study: 30413378

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-5)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-3A)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP3B)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP4-5)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (all patients)
Number of subjects: 276
Study: 30413396

Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg orally once daily for 12 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg
Number of subjects: 125
Study: 30413399

Group type: EXPERIMENTAL
Intervention: Interactive Nutrition Comics (INC) Web-based tool
Number of subjects: 89

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 89
Study: 30413504

Group type: EXPERIMENTAL
Intervention: HIV self-test
Number of subjects: 104
Study: 30413517

Group type: EXPERIMENTAL
Intervention: Biomarkers of Acute Serious Illness in Children study (BASIC) intervention including genomic, transcriptomic, proteomic and metabolomic analyses of blood, urine, stool and throat swabs.
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires assessing quality of life and child behaviour.
Number of subjects: 1017
Study: 30413543

Group type: EXPERIMENTAL
Intervention: Interactive Mobile Doctor (iMD) intervention
Number of subjects: 47
Study: 30413546

Group type: EXPERIMENTAL
Intervention: Medicaid-insured visit rates in expansion states
Number of subjects: 872378

Group type: COMPARATOR
Intervention: Privately insured visit rates in nonexpansion states
Number of subjects: 872378

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin screenings in expansion states
Number of subjects: 872378
Study: 30413559

Group type: EXPERIMENTAL
Intervention: Online family problem-solving treatment (OFPST)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 359
Study: 30413669

Group type: EXPERIMENTAL
Intervention: MBC-11 (0.5-10 mg/kg per day, administered daily for 5 days of every 4 weeks for up to four cycles)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MBC-11
Number of subjects: 15
Study: 30413829

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Non-pharmacological therapy
Number of subjects: 508
Study: 30413837

Group type: EXPERIMENTAL
Intervention: 10 mg everolimus once daily + 50 mg CTX once daily
Number of subjects: 40
Study: 30413960

Group type: EXPERIMENTAL
Intervention: 3D-FLAIR sequences
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SSFP sequences
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30
Study: 30414054

Group type: EXPERIMENTAL
Intervention: micro-fluid challenge (micro-FC; rapid central infusion of 50 ml)
Number of subjects: 61

Group type: COMPARATOR
Intervention: traditional fluid challenge (FC; 5 ml/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: extrasystolic method
Number of subjects: 61
Study: 30414064

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID and 10 mg BID
Number of subjects: 710
Study: 30414302

Group type: EXPERIMENTAL
Intervention: Presence of Hemorrhagic Transformation (HT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ECASS classification of HT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Decision to reintroduce antiplatelet therapy
Number of subjects: 30
Study: 30415208

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) serum levels
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: high-sensitive troponin T (hs-TnT) serum levels
Number of subjects: 1754
Study: 30415451

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg subcutaneously (SC) monthly
Number of subjects: 1458
Study: 30415608

Group type: EXPERIMENTAL
Intervention: Specialized palliative home care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oncological treatment
Number of subjects: 0
Study: 30416054

Group type: EXPERIMENTAL
Intervention: Alpha-1 MP (Prolastin)
Number of subjects: 4
Study: 30416770

Group type: EXPERIMENTAL
Intervention: Neutrophil/lymphocyte ratio (NLR) >11
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Leukocyte levels >10.5×10^9/L
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) values
Number of subjects: 269
Study: 30416787

Group type: EXPERIMENTAL
Intervention: Lung protective strategy with low tidal volume (Vt) (≤8 mL/kg) and limitation of the plateau pressure (Pplat) (≤30 cmH2O)
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: General acceptance of low Vt and limited Pplat
Number of subjects: 1814
Study: 30416992

Group type: EXPERIMENTAL
Intervention: Implementation intervention using Intervention Mapping
Number of subjects: 0
Study: 30417511

Group type: EXPERIMENTAL
Intervention: Sentinel node (SN) procedure
Number of subjects: 27
Study: 30417539

Group type: EXPERIMENTAL
Intervention: i-IFTA
Number of subjects: 108
Study: 30418117

Group type: EXPERIMENTAL
Intervention: mavrilimumab + methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate alone
Number of subjects: 0
Study: 30418357

Group type: EXPERIMENTAL
Intervention: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter for 10-35 days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 49
Study: 30418358

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Pertussis vaccination
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Discussion confidence among HCPs regarding pertussis vaccination
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Preferred site for vaccine administration among HCPs
Number of subjects: 314